JNJ 48816274Alternative Names: JNJ-48816274
Latest Information Update: 04 Aug 2016
At a glance
- Originator Janssen-Cilag
- Class Sleep disorder therapies
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Insomnia
Most Recent Events
- 28 Jul 2016 Janssen-Cilag International plans a first-in-human phase I trial in Healthy volunteers in USA (PO) (NCT02852395)
- 11 Jul 2016 Preclinical trials in Insomnia in Netherlands (PO) before July 2016